ライフサイエンスコーパス: dopaminergic drug

1 enes on cognition in patients receiving anti-dopaminergic drugs.

2 gery, cognitive dysfunction and influence of dopaminergic drugs.

3 Levodopa is the most potent of the dopaminergic drugs.

4 d as a template for assessing the effects of dopaminergic drugs.

5 ctory and need the introduction of novel non-dopaminergic drugs.

6 he locomotor activity stimulation typical of dopaminergic drugs.

7 n CST systems can be profoundly modulated by dopaminergic drugs.

8 under identical conditions, but received no dopaminergic drugs.

9 ts into the potential mechanism of action of dopaminergic drugs.

10 he nature of compulsive behaviors induced by dopaminergic drugs.

11 Dopaminergic drugs affect a variety of cognitive process

12 Previous data suggest that dopaminergic drugs affect the speed of this internal sto

13 learning models and show that treatment with dopaminergic drugs alters choice behavior in a manner co

14 worsened by stress, acute administration of dopaminergic drugs, and by subtle deficits in motor coor

15 Dopaminergic drugs are known to increase risk-taking beh

16 PKA, whereas the acute locomotor effects of dopaminergic drugs are relatively unaffected by this PKA

17 h blunted sensitivity when patients were OFF dopaminergic drugs, both in pupillary response and sacca

18 ced sensitivity of Akt-mediated signaling to dopaminergic drugs but retain the action of these drugs

19 r in humans can be directly manipulated by a dopaminergic drug, but that the effectiveness of such a

20 s and after the induction of mild dry eye or dopaminergic drug challenges.

21 PD patients treated with dopaminergic drugs demonstrated enhanced verbal and visu

22 dopaminergic signaling and effectiveness of dopaminergic drugs depend on the relative preponderance

23 clinical finding that in Parkinson's disease dopaminergic drugs especially impact on bradykinesia but

24 rexpressed in striatal neurons after chronic dopaminergic drug exposure, is suspected to mediate thes

25 ng long-term deleterious effects of repeated dopaminergic drug exposure.

26 ing in vivo and in vitro treatments with the dopaminergic drugs haloperidol, bromocriptine, and quinp

27 s identified using an acute challenge with a dopaminergic drug in healthy individuals can be used to

28 Gait and balance disorders unresponsive to dopaminergic drugs in Parkinson's disease (PD) are secon

29 The role of dopaminergic drugs in treating the various non-motor pro

30 Rather, levodopa or other short-acting dopaminergic drugs induce molecular changes and altered

31 vious single-cell experiments, the effect of dopaminergic drugs on imaging single vesicle exocytotic

32 ort of both clock and attentional effects of dopaminergic drugs on interval timing in the same experi

33 We observed no effect of dopaminergic drugs on learning from negative outcomes.

34 gree of predictability of clinical effect of dopaminergic drugs on motor symptoms in humans.

35 prove useful in the study of the effects of dopaminergic drugs on neuronal function in primary cultu

36 Additionally, the effects of dopaminergic drugs on the mRNA expression for the neurop

37 The effects of dopaminergic drugs on the mRNA level of APN and NEP 24.1

38 ality account for the contrasting effects of dopaminergic drugs on working memory and associated fron

39 ase, long-acting or continuous infusion of a dopaminergic drug reduces the risk of motor complication

40 Dopaminergic drugs remain the mainstay of Parkinson's di

41 More specifically, we found that dopaminergic drugs selectively modulate learning from po

42 se receptors, our molecular understanding of dopaminergic drug selectivity and design remains clouded

43 motor neuron regeneration can be boosted by dopaminergic drugs, similar to adult regeneration.

44 Contrary to expectation, we found that dopaminergic drug state (ON or OFF) did not impact learn

45 After treatment with dopaminergic drugs, the Piper mode of muscle discharge w

46 effects on cognition in the context of anti-dopaminergic drug therapy.

47 otor responses after acute administration of dopaminergic drugs, they display abnormalities in two ex

48 uropeptidase activity changes in response to dopaminergic drug treatment.

49 Given the clinical prevalence of dopaminergic drugs, understanding the relationship betwe

50 However, clinical responses to dopaminergic drugs vary substantially from person to per

51 ation proposes that continuous delivery of a dopaminergic drug will prevent pulsatile stimulation and

52 audate nucleus was modulated specifically by dopaminergic drugs, with opposing effects of sulpiride a